Akinion Pharmaceuticals appoints Carl Harald Janson as CEO
(Thomson Reuters ONE) -
STOCKHOLM, SWEDEN - January 9, 2012. Akinion Pharmaceuticals AB, a Karolinska
Development AB portfolio company, announced today the appointment of Carl Harald
Janson as new CEO. Carl Harald Janson, MD, PhD and CEFA, has over 25 years of
experience in medicine, pharmaceutical development and asset management.
"We are very pleased to see Carl Harald Janson as new CEO in Akinion", says
Ingemar Aldén, Chairman of Akinion. "Carl Harald has been a board member of
Akinion since its inception. His broad experience in pharmaceutical development
will be of great benefit to the company."
"I am much honored and excited to lead the experienced team of Akinion to take
AKN-028 into clinical development stage. If the unique preclinical efficacy of
AKN-028 translates into a comparable clinical benefit, then I am confident that
AKN-028 could become a new important treatment for patients with acute myeloid
leukemia", says Carl Harald Janson, CEO, Akinion.
Carl Harald Janson served as Investment Manager at Karolinska Development from
2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a
Certified European Financial Analyst (CEFA) from Stockholm School of Economics.
Carl Harald has over 25 years of experience in medicine, pharmaceutical
development and asset management including from Astra Arcus, Hagströmer &
Qviberg Fondkommission, Danske Securities and Carnegie Investment Bank. He is
currently Chairman of the Board of Dilaforette Holding and Board Director of
Axelar, Oncopeptides, Clanotech and Akinion Pharmaceuticals.
For further information, please contact:
Ingemar Aldén, Chairman of Akinion Pharmaceuticals AB
Phone: +46 (0) 70 530 84 82, e-mail:ingemar.alden(at)aldenco.se
TO THE EDITORS
About Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB is a Swedish biotech company founded in 2009. The
company is developing kinase receptor inhibitors for treatment of acute myeloid
leukemia. Akinion Pharmaceuticals is part of the Karolinska Development
portfolio of companies.www.akinion.com
Akinion Pharmaceuticals appoints Carl Harald Janson as CEO:
http://hugin.info/144419/R/1575838/490898.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Akinion via Thomson Reuters ONE
[HUG#1575838]
Unternehmensinformation / Kurzprofil:
Datum: 09.01.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 101933
Anzahl Zeichen: 2954
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Akinion Pharmaceuticals appoints Carl Harald Janson as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Akinion (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
